Ankarys Therapeutics

Ankarys Therapeutics is a Swiss biotechnology company focused on developing a new class of precision oncology treatments that target aneuploidy, a hallmark of cancer characterized by an abnormal number of chromosomes. By leveraging a proprietary platform to identify aneuploidy-selective synthetic lethal interactions, the company aims to selectively eliminate cancer cells while sparing healthy, euploid cells. Their approach addresses a significant unmet need in oncology, as aneuploidy is present in the vast majority of solid tumors and is often associated with poor prognosis and resistance to standard therapies. The company is currently advancing a pipeline of small molecule inhibitors designed to exploit these unique chromosomal vulnerabilities.